Biodesix, Inc. (BDSX)

NASDAQ: BDSX · Real-Time Price · USD
6.62
+0.20 (3.12%)
At close: Oct 20, 2025, 4:00 PM EDT
6.49
-0.13 (-1.96%)
After-hours: Oct 20, 2025, 4:55 PM EDT
3.12%
Market Cap51.64M
Revenue (ttm)76.56M
Net Income (ttm)-41.08M
Shares Out 7.80M
EPS (ttm)-5.60
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume77,039
Open6.71
Previous Close6.42
Day's Range6.34 - 6.75
52-Week Range3.44 - 34.40
Beta0.98
AnalystsStrong Buy
Price Target32.50 (+390.94%)
Earnings DateNov 3, 2025

About BDSX

Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to... [Read more]

Sector Healthcare
IPO Date Oct 28, 2020
Employees 273
Stock Exchange NASDAQ
Ticker Symbol BDSX
Full Company Profile

Financial Performance

In 2024, Biodesix's revenue was $71.32 million, an increase of 45.30% compared to the previous year's $49.09 million. Losses were -$42.93 million, -17.67% less than in 2023.

Financial Statements

Analyst Summary

According to 5 analysts, the average rating for BDSX stock is "Strong Buy." The 12-month stock price target is $32.5, which is an increase of 390.94% from the latest price.

Price Target
$32.5
(390.94% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Biodesix to Report Third Quarter 2025 Financial Results on November 3, 2025

LOUISVILLE, Colo., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the third quarter...

14 hours ago - GlobeNewsWire

Biodesix Announces Presentations and Events at the CHEST 2025 Annual Meeting

One year after launch of real-world CLARIFY study, preliminary data from the first 1,000 enrolled patients will be presented One year after launch of real-world CLARIFY study, preliminary data from th...

5 days ago - GlobeNewsWire

Biodesix Unveils October Lung Health Events in Colorado with the Association of Pulmonary Advanced Practice Providers (APAPP), American Lung Association in Colorado, and GO2 for Lung Cancer Centers of Excellence Summit

Biodesix partners with three leading Lung Health organizations to bring education and advocacy to healthcare professionals and patients

14 days ago - GlobeNewsWire

Biodesix Announces One-for-Twenty Reverse Stock Split

LOUISVILLE, Colo., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX) (“Biodesix” or the “Company”), a leader in personalized diagnostics, today announced a one-for-twenty reverse stock ...

5 weeks ago - GlobeNewsWire

Biodesix to Participate in Lake Street Capital Markets' 9th Annual Best Ideas Growth (BIG9) Conference

LOUISVILLE, Colo., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Robin Cowie, Chief Financial Officer, will host in-person 1...

6 weeks ago - GlobeNewsWire

Biodesix Recognized as a Thermo Fisher Scientific Center of Excellence (COE) for NGS Diagnostics

Biodesix recently validated Thermo Fisher's tissue-based Oncomine Dx Express Test for solid tumors on the Genexus Dx Integrated Sequencer Biodesix recently validated Thermo Fisher's tissue-based Oncom...

2 months ago - GlobeNewsWire

Biodesix, Inc. (BDSX) Q2 2025 Earnings Call Transcript

Biodesix, Inc. (NASDAQ:BDSX) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Robin Harper Cowie - CFO, Secretary & Treasurer Scott Hutton - President, CEO & Director C...

2 months ago - Seeking Alpha

Biodesix Announces Second Quarter 2025 Results and Highlights

Q2 2025 Revenue of $20.0 million, an increase of 12% over Q2 2024; Q2 2025 gross profit margin of 80%, a 150-basis point improvement from Q2 2024; Reiterating FY2025 Total Revenue Guidance of $80-85 m...

2 months ago - GlobeNewsWire

Biodesix to Present at the Canaccord Genuity 45th Annual Growth Conference

BOULDER, Colo., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief F...

2 months ago - GlobeNewsWire

Biodesix to Report Second Quarter 2025 Financial Results on August 7, 2025

LOUISVILLE, Colo., July 24, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the second quarte...

3 months ago - GlobeNewsWire

Biodesix Partners with Association of Pulmonary Advanced Practice Providers (APAPP) to Deliver Nation's First Medical Education for APPs on Biomarkers in Lung Nodule and Lung Cancer Programs

Nation's first CME-accredited course for APPs on clinical application of diagnostic biomarkers in Lung Nodule and Lung Cancer patient programs Nation's first CME-accredited course for APPs on clinical...

4 months ago - GlobeNewsWire

Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting

LOUISVILLE, Colo., May 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced today that new data will be presented at the 2025 American Society ...

5 months ago - GlobeNewsWire

Biodesix to Participate in Upcoming Investor Conferences

LOUISVILLE, Colo., May 21, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that members of the Biodesix management team, will participat...

5 months ago - GlobeNewsWire

Biodesix Announces New Clinical and Economic Data for its Nodify Lung® Tests at ISPOR and ATS

LOUISVILLE, Colo., May 15, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced that new data will be presented at the International Society for Ph...

5 months ago - GlobeNewsWire

Denver Post Names Biodesix a Winner of Top Workplaces 2025 Award

LOUISVILLE, Colo., May 14, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, is pleased to announce that it is a Colorado Top Workplaces 2025 Winner.

5 months ago - GlobeNewsWire

Biodesix, Inc. (BDSX) Q1 2025 Earnings Call Transcript

Biodesix, Inc. (NASDAQ:BDSX) Q1 2025 Results Conference Call May 13, 2025 4:30 PM ET Company Participants Chris Brinzey - Investor Relations Scott Hutton - Chief Executive Officer Robin Harper Cowie ...

5 months ago - Seeking Alpha

Biodesix Announces First Quarter 2025 Results and Highlights

Total Q1 2025 Revenue of $18.0 million, an increase of 21% over Q1 2024; Gross margins of 79.4% for Q1 2025 ; Q1 2025 Net loss improved by 18% compared to Q1 2024; Updated 2025 Revenue Guidance to a r...

5 months ago - GlobeNewsWire

Biodesix to Report First Quarter 2025 Financial Results on May 13, 2025

LOUISVILLE, Colo., April 29, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the first quarte...

6 months ago - GlobeNewsWire

Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types

Aggregate analysis of eight clinical trials of patients with advanced non-small cell lung cancer (aNSCLC) was supported by Biodesix, using Bio-Rad Droplet Digital™ PCR technology Aggregate analysis of...

6 months ago - GlobeNewsWire

Biodesix, Inc. (BDSX) Q4 2024 Earnings Call Transcript

Biodesix, Inc. (NASDAQ:BDSX) Q4 2024 Earnings Conference Call March 3, 2025 4:30 PM ET Company Participants Chris Brinzey - Investor Relations Scott Hutton - Chief Executive Officer Robin Harper Cowi...

8 months ago - Seeking Alpha

Biodesix Announces Fourth Quarter and Fiscal Year 2024 Results

Total Revenue of $71.3 million for FY2024, growing 45% over FY2023; Gross margins of 78% for FY2024, up 5% points over FY2023 ; FY2025 Total Revenue Guidance of $92-95 million; Conference Call and Web...

8 months ago - GlobeNewsWire

Biodesix to Present at TD Cowen 45th Annual Health Care Conference

BOULDER, Colo., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief F...

8 months ago - GlobeNewsWire

Biodesix to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

BOULDER, Colo., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the fourth quarter a...

8 months ago - GlobeNewsWire

Biodesix Announces Preliminary Fourth Quarter and Full-Year 2024 Results (Unaudited)

Grew full-year revenue to an estimated $71.3 million, an increase of 45% Grew full-year revenue to an estimated $71.3 million, an increase of 45%

10 months ago - GlobeNewsWire

Biodesix Announces Publication of a New Nodify CDT® Clinical Validation Study

Analysis of 447 patients receiving the Nodify CDT blood-based lung nodule test published in CHEST Pulmonary Journal reaffirms test performance Analysis of 447 patients receiving the Nodify CDT blood-b...

10 months ago - GlobeNewsWire